MA54975A1 - Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation - Google Patents

Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Info

Publication number
MA54975A1
MA54975A1 MA54975A MA54975A MA54975A1 MA 54975 A1 MA54975 A1 MA 54975A1 MA 54975 A MA54975 A MA 54975A MA 54975 A MA54975 A MA 54975A MA 54975 A1 MA54975 A1 MA 54975A1
Authority
MA
Morocco
Prior art keywords
pcrv
antibodies
bind
methods
compositions
Prior art date
Application number
MA54975A
Other languages
English (en)
Other versions
MA54975B1 (fr
Inventor
Christos Kyratsous
Alida Coppi
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA54975A1 publication Critical patent/MA54975A1/fr
Publication of MA54975B1 publication Critical patent/MA54975B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient à pseudomonas aeruginosa pcrv, et des méthodes d'utilisation de ceux-ci. Selon certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient à pcrv. Les anticorps anti-pcrv et les fragments de liaison à l'antigène sont utiles pour la prévention et le traitement d'infections par p. Aeruginosa.
MA54975A 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation MA54975B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11
PCT/US2020/037008 WO2020252029A1 (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA54975A1 true MA54975A1 (fr) 2022-05-31
MA54975B1 MA54975B1 (fr) 2023-08-31

Family

ID=71948699

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056205A MA56205A (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA54975A MA54975B1 (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA056205A MA56205A (fr) 2019-06-11 2020-06-10 Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation

Country Status (16)

Country Link
US (2) US11655286B2 (fr)
EP (1) EP3983015A1 (fr)
JP (1) JP2022536469A (fr)
KR (1) KR20220019755A (fr)
CN (1) CN113966343A (fr)
AU (1) AU2020292283A1 (fr)
BR (1) BR112021023335A2 (fr)
CA (1) CA3140075A1 (fr)
CL (4) CL2021003215A1 (fr)
CO (1) CO2021015254A2 (fr)
EA (1) EA202192810A1 (fr)
IL (1) IL288727A (fr)
MA (2) MA56205A (fr)
MX (1) MX2021015156A (fr)
SG (1) SG11202112462RA (fr)
WO (1) WO2020252029A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6182152B2 (ja) * 2011-11-07 2017-08-16 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN118440191A (zh) * 2024-05-11 2024-08-06 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1353688T3 (da) 2001-01-26 2007-04-10 Mcw Res Found Inc Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2009073631A2 (fr) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Anticorps dirigés contre l'antigène pcrv de pseudomonas aeruginosa
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
MX2011009100A (es) * 2009-03-11 2011-09-27 Shionogi & Co Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal.
EP3916011A1 (fr) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
WO2012122533A2 (fr) 2011-03-10 2012-09-13 The University Of Chicago Compositions et procédés liés à des anticorps contre les protéines staphylococciques isda ou isdb
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
JP6182152B2 (ja) 2011-11-07 2017-08-16 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
WO2013096948A1 (fr) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulines et variants dirigés contre des microbes pathogènes
EP2917236A2 (fr) * 2012-11-06 2015-09-16 MedImmune, LLC Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
CN108368149A (zh) * 2015-11-30 2018-08-03 免疫医疗有限公司 用于预防或治疗医源性肺炎的方法
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos

Also Published As

Publication number Publication date
IL288727A (en) 2022-02-01
CL2021003215A1 (es) 2022-09-30
CN113966343A (zh) 2022-01-21
EA202192810A1 (ru) 2022-03-05
MA54975B1 (fr) 2023-08-31
CO2021015254A2 (es) 2021-11-19
SG11202112462RA (en) 2021-12-30
MX2021015156A (es) 2022-01-18
KR20220019755A (ko) 2022-02-17
US20200392210A1 (en) 2020-12-17
CL2023003696A1 (es) 2024-06-14
EP3983015A1 (fr) 2022-04-20
WO2020252029A1 (fr) 2020-12-17
CL2023003695A1 (es) 2024-06-14
CA3140075A1 (fr) 2020-12-17
JP2022536469A (ja) 2022-08-17
US11655286B2 (en) 2023-05-23
CL2023003694A1 (es) 2024-06-14
AU2020292283A1 (en) 2021-12-23
MA56205A (fr) 2022-04-20
BR112021023335A2 (pt) 2022-01-04
US20230322907A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MA54975A1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA46731A (fr) Anticorps anti-tmprss2 et fragments de liaison à l'antigène
WO2020039321A8 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
TN2018000341A1 (en) ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
MA33387B1 (fr) Polypeptides et procede de traitement
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
WO2021212049A3 (fr) Anticorps monoclonaux anti-sars-cov-2
MA44234B1 (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA201190163A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К PcrV, ОБЛАДАЮЩЕЕ АКТИВНОСТЬЮ ПРОТИВ ПСЕВДОМОНАС
WO2022023566A3 (fr) Anticorps anti-cd-3 pour le traitement du coronavirus
SE8702734D0 (sv) Monoclonal antibodies to pseudomonas aeruginosa flagella
MA48870B1 (fr) Anticorps anti-sortiline et leurs méthodes d'utilisation
MA53186A1 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MA55234A1 (fr) Fragments de liaison à l'antigène cd3 et compositions les comprenant
WO2020257633A3 (fr) Anticorps monoclonaux dirigés contre le virus jc
MA51590B2 (fr) Anticorps anti-msr1 et leurs procédés d'utilisation
MA50737B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient